Cencora, Inc. $COR Shares Sold by Staley Capital Advisers Inc.

Staley Capital Advisers Inc. lessened its holdings in shares of Cencora, Inc. (NYSE:COR) by 25.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,087 shares of the company’s stock after selling 2,100 shares during the period. Staley Capital Advisers Inc.’s holdings in Cencora were worth $2,056,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Cencora by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after buying an additional 221,570 shares during the period. State Street Corp grew its position in Cencora by 9.3% during the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after buying an additional 782,911 shares during the period. JPMorgan Chase & Co. grew its position in Cencora by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after buying an additional 821,098 shares during the period. Boston Partners grew its position in Cencora by 2.0% during the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after buying an additional 89,506 shares during the period. Finally, Wellington Management Group LLP grew its position in Cencora by 3.0% during the third quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock worth $1,241,094,000 after buying an additional 115,278 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Down 1.6%

COR opened at $256.96 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The firm has a market cap of $49.99 billion, a P/E ratio of 19.71, a PEG ratio of 1.19 and a beta of 0.64. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The business’s fifty day simple moving average is $314.65 and its 200 day simple moving average is $339.22.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same quarter last year, the business posted $4.42 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.76 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is 18.40%.

Analyst Ratings Changes

COR has been the topic of several research reports. Morgan Stanley set a $342.00 target price on Cencora in a report on Friday, May 8th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Barclays upped their target price on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Citigroup lowered their target price on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.